Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor BridgeBio Pharma
Historische aandelenkoersen
Huidige aandelenkoers	US$84.48
52 Week Hoogtepunt	US$93.42
52 Week Laag	US$46.29
Bèta	0.98
1 maand verandering	-1.64%
3 maanden verandering	30.61%
1 Jaar Verandering	81.37%
3 jaar verandering	171.90%
5 jaar verandering	68.56%
Verandering sinds IPO	206.64%

Recent nieuws en updates

Narratiefupdate • Jul 25

BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside

BridgeBio Pharma's fair value estimate has been revised slightly higher to $105.26 per share from $102.71, as analysts refresh models around updated price targets and pipeline expectations, particularly for Attruby, acoramidis and BBP-418. Analyst Commentary Recent research updates on BridgeBio Pharma reflect a mix of optimism and caution, with analysts recalibrating price targets as Attruby, acoramidis, BBP-418 and infigratinib progress through launch and regulatory milestones.

Nieuw narratief • Jul 19

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.

Seeking Alpha • Jul 12

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

Summary BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market. Recent $1B preferred equity raise secures BBIO's cash runway for at least 12 months, supporting ongoing NDA submissions and commercialization efforts. Read the full article on Seeking Alpha

Recent updates

Narratiefupdate • Jul 25

BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside

Nieuw narratief • Jul 19

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Seeking Alpha • Jul 12

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

Narratiefupdate • Jul 11

BBIO: Cardiomyopathy Launch And Rare Disease Filings Will Shape Next Phase

The analyst fair value estimate for BridgeBio Pharma has been raised from $76.00 to $80.00, reflecting updated Street price targets around $96 to $104 and analyst views that recent regulatory progress and ongoing launch execution support slightly higher projected growth, margins, and future P/E. Analyst Commentary Recent research on BridgeBio Pharma shows a mix of optimism around its rare disease portfolio and a more cautious stance from some bearish analysts who are focused on execution and valuation risks.

Narratiefupdate • Jun 22

BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares

BridgeBio Pharma's updated analyst price target framework reflects a modestly higher fair value estimate of about $136, as analysts factor in mixed Street revisions that incorporate recent Q1 model updates, new coverage tied to Attruby and the rare disease pipeline, and differing views on payer risks and the recent regulatory milestones. Analyst Commentary Street commentary on BridgeBio Pharma currently reflects a mix of enthusiasm around Attruby, the rare disease portfolio, and key regulatory updates, offset by caution around payer dynamics and how these factors could influence valuation over time.

Narratiefupdate • Jun 05

BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside

Analysts raised their blended fair value estimate for BridgeBio Pharma by about $1.82 to roughly $102.71, citing fresh price targets around $98 to $104, growing confidence in the Attruby launch, the broader rare disease pipeline, and added visibility from BBP-418's FDA Priority Review. Analyst Commentary Street research on BridgeBio Pharma is mixed, with several firms adjusting price targets and ratings around the Attruby launch, pipeline milestones, and regulatory updates such as the Priority Review for BBP-418.

Narratiefupdate • May 20

BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase

BridgeBio Pharma's fair value estimate has been trimmed by $4 to $76 as analysts balance a higher discount rate and more measured revenue growth against ongoing support for Attruby and the broader pipeline, as reflected in recent price target updates across the Street. Analyst Commentary Street research on BridgeBio continues to cluster around Attruby execution, valuation upside tied to pipeline milestones, and the impact of tafamidis settlement dynamics.

Narratiefupdate • May 01

BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside

Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.

Narratiefupdate • Apr 17

BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence

Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.

Narratiefupdate • Apr 03

BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares

Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.

Narratiefupdate • Mar 20

BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares

The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.

Narratiefupdate • Mar 05

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026

The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.

Narratiefupdate • Feb 19

BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase

The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.

Narratiefupdate • Feb 05

BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing

Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.

Narratiefupdate • Jan 22

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026

Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.

Narratiefupdate • Jan 07

BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing

Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.

Narratiefupdate • Dec 24

BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead

BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.

Narratiefupdate • Dec 10

BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond

Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.

Narratiefupdate • Nov 26

BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals

BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.

Narratiefupdate • Nov 10

BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions

BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.

Narratiefupdate • Oct 27

Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion

BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.

Narratiefupdate • Oct 13

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.

Narratiefupdate • Sep 29

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.

Narratiefupdate • Sep 14

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.

Narratiefupdate • Aug 30

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.

Nieuw narratief • Aug 10

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.

Analyse-artikel • Aug 09

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

NasdaqGS:BBIO 1 Year Share Price vs Fair Value Explore BridgeBio Pharma's Fair Values from the Community and select...

Rendement voor aandeelhouders

	BBIO	US Biotechs	US Markt
7D	5.5%	6.3%	4.2%
1Y	81.4%	40.9%	20.6%

Rendement versus industrie: BBIO overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 40.9 % opleverde.

Rendement versus markt: BBIO overtrof de US markt, die het afgelopen jaar een rendement opleverde van 20.6 %.

Prijsvolatiliteit

Is BBIO's price volatile compared to industry and market?
BBIO volatility
BBIO Average Weekly Movement	6.4%
Biotechs Industry Average Movement	10.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: BBIO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BBIO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	837	Neil Kumar	bridgebio.com

BridgeBio Pharma, Inc., een biofarmaceutisch bedrijf, ontdekt, ontwikkelt en levert medicijnen voor patiënten met genetische ziekten. Het bedrijf biedt Attruby, een volgende generatie orale kleine molecule die TTR bijna volledig stabiliseert voor de behandeling van cardiomyopathie van wild-type of transthyretine-gemedieerde amyloïdose (ATTR-CM); Fosdenopterine, een intraveneuze formulering van synthetisch cyclisch pyranopterinemonofosfaat voor de behandeling van molybdeencofactortekort onder de merknaam NULIBRY; en infigratinib in lage dosis, een orale FGFR1-3 selectieve tyrosinekinaseremmer, die zich in Fase 3 van de klinische fase bevindt voor de behandeling van kinderen met achondroplasie en hypochondroplasie. Het ontwikkelt ook Encaleret, een orale kleine molecule, negatieve allosterische modulator van de calcium sensing receptor, die zich in fase 3 van het klinisch onderzoek bevindt voor de behandeling van Autosomaal Dominante Hypocalcemie Type 1 (ADH1) en Chronische Hypoparathyreoïdie (CHP); BBP-418, een onderzoekstherapie met kleine moleculen die oraal wordt toegediend en zich in fase 3 van een klinische studie bevindt voor de behandeling van LGMD2I; en BBP-812, een onderzoekstherapie met adeno-geassocieerd virus (AAV) voor de ziekte van Canavan.

BridgeBio Pharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van BridgeBio Pharma zich tot de beurswaarde?
BBIO fundamentele statistieken
Marktkapitalisatie	US$16.51b
Inkomsten(TTM)	-US$721.55m
Inkomsten(TTM)	US$579.96m

28.5x

P/S-verhouding

-22.9x

Koers/Winstverhouding

Is BBIO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BBIO resultatenrekening (TTM)
Inkomsten	US$579.96m
Kosten van inkomsten	US$28.26m
Brutowinst	US$551.70m
Overige uitgaven	US$1.27b
Inkomsten	-US$721.55m

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Aug 10, 2026

Winst per aandeel (EPS)	-3.69
Brutomarge	95.13%
Nettowinstmarge	-124.41%
Schuld/Eigen Vermogen Verhouding	-109.0%

Hoe presteerde BBIO op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/08/09 12:04
Aandelenkoers aan het einde van de dag	2026/08/07 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

BridgeBio Pharma, Inc. wordt gevolgd door 37 analisten. 20 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Eliana Merle	Barclays
William Pickering	Bernstein
Jason Zemansky	BofA Global Research

BridgeBio Pharma (BBIO) Aandelenoverzicht

Beloningen

Risicoanalyse

Analyst Price Targets

Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion

Advances In Genomics And AI Will Expand Rare Disease Markets

Rising Global Price Controls And Costs Will Curb Future Prospects

Top Community Narratives

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Top Community Narratives

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Top Analyst Narratives

Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion

Advances In Genomics And AI Will Expand Rare Disease Markets

Rising Global Price Controls And Costs Will Curb Future Prospects

BridgeBio Pharma, Inc. Concurrenten

Ascendis Pharma

Arrowhead Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals

Prijsgeschiedenis en prestaties

Recent nieuws en updates

BridgeBio Pharma, Inc. to Report Q2, 2026 Results on Aug 10, 2026

BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside

FDA Accepts BridgeBio’s Encaleret Application for ADH1 Decision Expected in 2027

BridgeBio Pharma, Inc. Announces FDA Acceptance Of NDA For Encaleret For ADH1

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

Recent updates

BridgeBio Pharma, Inc. to Report Q2, 2026 Results on Aug 10, 2026

BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside

FDA Accepts BridgeBio’s Encaleret Application for ADH1 Decision Expected in 2027

BridgeBio Pharma, Inc. Announces FDA Acceptance Of NDA For Encaleret For ADH1

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

AstraZeneca and Ionis ATTR-CM Trial Miss Clears Competitive Path for BridgeBio Pharma

BBIO: Cardiomyopathy Launch And Rare Disease Filings Will Shape Next Phase

Independent Director notifies of intention to sell stock

BridgeBio Pharma, Inc. announced that it expects to receive $1 billion in funding from Chinotto Investments, LLC, HCRX Investments HoldCo, L.P. and other investors.

BridgeBio Pharma Raises $1 Billion in Preferred Equity to Fund Drug Launches

BridgeBio Pharma Announces New Analyses Demonstrating Early And Sustained Kidney-Protective Effects Of Acoramidis In ATTR-CM

BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 2000 Dynamic Index

BridgeBio Reports Positive Phase 3 Results for Infigratinib in Achondroplasia Trial

Bridgebio Pharma Presents Primary Results from Phase 3 Propel 3 Trial of Oral Infigratinib for Children Living with Achondroplasia At Iccbh 2026

BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares

BridgeBio Pharma Partners With DKSH to Advance ATTR-CM Drug in Asia Pacific Markets

BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside

Bridgebio Pharma Announces Fda Acceptance and Priority Review of Nda for Bbp-418 for Lgmd2i/R9

BridgeBio Wins FDA Priority Review for Potential First LGMD2I/R9 Therapy BBP-418

Co-Founder exercised options and sold US$2.4m worth of stock

BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase

Consensus EPS estimates fall by 12%, revenue upgraded

BridgeBio Pharma Submits NDA For Encaleret For Individuals Living With ADH1

BridgeBio Pharma Announces Disease-Modifying Effects of Acoramidis in ATTR-CM

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

BridgeBio Pharma, Inc. (NasdaqGS:BBIO) announces an Equity Buyback for $500 million worth of its shares.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside

BridgeBio Pharma, Inc. to Report Q1, 2026 Results on May 07, 2026

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2026

BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence

BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares

BridgeBio Pharma, Inc. Presents Long-Term Efficacy and Safety Data from the ATTRibute-CM Open-Label Extension (OLE) Trial

Bridgebio Pharma, Inc. Submits Nda to Fda for Bbp-418 for Individuals Living with Lgmd2i/R9

BridgeBio Pharma Announces Long-Term Efficacy And Safety Data For Acoramidis In Patients With ATTR-CM

BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares

Co-Founder notifies of intention to sell stock

Bridgebio Pharma, Inc. Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Independent Director notifies of intention to sell stock

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026

BridgeBio Pharma, Inc. Presents Additional Data from Phase 3 Fortify Trial of BBP-418 for LGMD2I/R9

Consensus EPS estimates fall by 14%

Full year 2025 earnings: EPS misses analyst expectations

BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase

Independent Director notifies of intention to sell stock

BridgeBio Pharma, Inc. to Report Q4, 2025 Results on Feb 24, 2026

BridgeBio Pharma, Inc. Announces Positive Topline Results from PROPEL 3, Global Phase 3 Pivotal Study of Oral Infigratinib in Children Living with Achondroplasia

BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026

Co-Founder notifies of intention to sell stock